Low molecular weight heparins [carb, phsu]
Managing [ocac]
Occlusive [ftcn]
crises [fndg]
People [popg]
Sickle Cell Disease [dsyn]
Sickle Cell Disease [dsyn]
Severe disorder [fndg]
GENETIC [topp]
World [popg]
divided [ftcn]
Phenotypes [orga]
Characterized [acty]
Hemolysis [patf]
Occlusion [ortf]
Pain [sosy]
Prominent [qlco]
Symptom [sosy]
Occlusion [ortf]
Hypercoagulability [dsyn]
Well [qlco]
Established [qlco]
Pathogenic [orgm]
Phenomenon [phpr]
People [popg]
Sickle Cell Disease [dsyn]
Low molecular weight heparins [carb, phsu]
Hypercoagulable state [dsyn]
Anticoagulant effect [ortf]
Update [tmco]
Published [ocac]
Version [ftcn]
objectives [inpr]
effects [qlco]
Low molecular weight heparins [carb, phsu]
Managing [ocac]
Occlusive [ftcn]
crises [fndg]
People [popg]
Sickle Cell Disease [dsyn]
search [inpr]
Methods [inpr]
Searched [acty]
Cystic Fibrosis [dsyn]
Genetic Disorders [dsyn]
Group [idcn]
haemoglobinopathies [dsyn]
Trial [resa]
Comprise [acty]
Reference [idcn]
Identified [qlco]
Comprehensive [qlco]
Database, Electronic [inpr]
search [inpr]
Searched [acty]
Abstract [ocac]
Books [inpr]
conference proceedings [inpr]
Several [qnco]
Trial [resa]
Registries [inpr]
ONGOING [idcn]
Trial [resa]
Date [tmco]
Last [qlco]
search [inpr]
Cystic Fibrosis [dsyn]
Genetic Disorders [dsyn]
Group [idcn]
haemoglobinopathies [dsyn]
Trial [resa]
Selection Criteria [qlco]
Controlled Clinical Trial [inpr]
Controlled Clinical Trial [inpr]
Assessed [acty]
effects [qlco]
Low molecular weight heparins [carb, phsu]
Management [ocac]
Occlusive [ftcn]
crises [fndg]
People [popg]
Sickle Cell Disease [dsyn]
Data Collection [resa]
Study [mnob]
Data Extraction [resa]
Assessment [hlca]
Bias [idcn]
carried [acty]
Out [spco]
Authors [prog]
Main [qlco]
participants [popg]
included [ftcn]
Study [mnob]
High Risk [qlco]
Bias [idcn]
participants [popg]
Quality [qlco]
Very low [fndg]
Study [mnob]
Reported [inpr]
Pain severity [clna]
tinzaparin [carb, phsu]
Group [idcn]
placebo [topp]
Group [idcn]
P NOS [aapp, imft]
Analysis of Variance [qnco]
P NOS [aapp, imft]
Analysis of Variance [qnco]
tinzaparin [carb, phsu]
Rapid [qlco]
Resolution [idcn]
Pain [sosy]
Measured [qlco]
Numerical Scale [inpr]
Pain [sosy]
Duration [tmco]
Pain crisis [fndg]
statistically significant [qnco]
days [tmco]
tinzaparin [carb, phsu]
Group [idcn]
participants [popg]
treated [topp]
tinzaparin [carb, phsu]
Statistically [ocdi]
Hospitalization [hlca]
days [tmco]
participants [popg]
Group [idcn]
treated [topp]
placebo [topp]
4 Days [tmco]
Minor [popg]
Bleeding [patf]
Events [evnt]
Reported [inpr]
adverse events [fndg]
tinzaparin [carb, phsu]
Group [idcn]
Reported [inpr]
placebo [topp]
Group [idcn]
Second [qnco]
Study [mnob]
Bias [idcn]
Including [ftcn]
participants [popg]
Conference [hcpp]
Abstract [ocac]
Limited [ftcn]
Address [inpr]
i e [diap, inpr]
Pain intensity [clna]
Pain intensity [clna]
Reduced [qlco]
Reported [inpr]
Visual Analog Scale [diap]
Dalteparin [carb, phsu]
Group [idcn]
placebo [topp]
Group [idcn]
Quality [qlco]
Rated [acty]
Very low [fndg]
reasons [idcn]
Quality [qlco]
Serious [qlco]
Bias [idcn]
IMPRECISION [phpr]
Sample Size [qnco]
occurrence [ftcn]
Events [evnt]
Authors [prog]
Conclusions [idcn]
Based [ftcn]
Incomplete [qnco]
Support [medd]
Effectiveness [qlco]
Low molecular weight heparins [carb, phsu]
People [popg]
Sickle Cell Disease [dsyn]
Occlusive [ftcn]
crises [fndg]
Sickle Cell Disease [dsyn]
Well [qlco]
Design [acty]
placebo controlled study [inpr, resa]
Types [qlco]
Low molecular weight heparins [carb, phsu]
participants [popg]
Genotypes [orga]
Sickle Cell Disease [dsyn]
Need [qlco]
carried [acty]
Out [spco]
Dismiss [acty]
Single [popg]
Study [mnob]
